CLAIMS:

1. An anti-TNF antibody or binding fragment thereof comprising a heavy chain or heavy chain fragment having a variable region, wherein said variable region comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3.
2. An anti-TNF antibody or binding fragment thereof according to claim 1, wherein the antibody or binding fragment further comprises a light chain or fragment thereof having a variable region comprising three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4 or 5, CDR L2 has the sequence given in SEQ ID NO: 6, 7, 8 or 9 and CDR L3 has the sequence given in SEQ ID NO: 10.
3. An anti-TNF antibody or binding fragment thereof according to claim 2, where the CDR L1 has the sequence given in SEQ ID NO: 4.
4. An anti-TNF antibody or binding fragment thereof according to claim 2, where the CDR L1 has the sequence given in SEQ ID NO: 5.
5. An anti-TNF antibody or binding fragment thereof according to any one of claims 2 to 4, wherein CDR L2 has the sequence given in SEQ ID NO: 6.
6. An anti-TNF antibody or binding fragment thereof according to any one of claims 2 to 4, wherein CDR L2 has the sequence given in SEQ ID NO: 7.
7. An anti-TNF antibody or binding fragment thereof according to any one of claims 2 to 4, wherein CDR L2 has the sequence given in SEQ ID NO: 8.
8. An anti-TNF antibody or binding fragment thereof according to any one of claims 2 to 4, wherein CDR L2 has the sequence given in SEQ ID NO: 9.
9. An anti-TNF antibody or binding fragment thereof according to claim 1 or claim 2 having a heavy chain comprising the sequence given in SEQ ID NO: 12, 16 or 28.
10. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 3 having a light chain comprising the sequence given in SEQ ID NO: 11, 15 or 27.
11. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 4, having a heavy chain comprising the sequence given in SEQ ID NO: 12 and a light chain comprising the sequence given in SEQ ID NO: 11.
12. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 4, having a heavy chain comprising the sequence given in SEQ ID NO: 16 and a light chain comprising the sequence given in SEQ ID NO: 15.
13. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 4, having a heavy chain comprising the sequence given in SEQ ID NO: 28 and a light chain comprising the sequence given in SEQ ID NO: 27.

14. An anti-TNF antibody or binding fragment thereof according to claim 1 or claim 2, wherein the antibody is humanized.
15. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 14, wherein the antibody or binding fragment is a scFv, dsscFv, Fv, Fab, Fab', Fab-Fv, or Fab-dsFv fragment.
16. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 15, wherein the antibody or binding fragment is conjugated to a polymer for example selected from starch, albumin and polyethylene glycol.
17. An anti-TNF antibody or binding fragment thereof according to claim 16, wherein the polymer is PEG, for example with a molecular weight in the range 5 to 50kDa.
18. An anti-TNF antibody according to any one of claims 1 to 14, wherein the antibody is a full length antibody.
19. An anti-TNF antibody according to claim 18, wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.
20. An anti-TNF antibody or binding fragment thereof which binds to the same epitope of human TNF as the antibody of claim 11 to 13.
21. An anti-TNF antibody or binding fragment thereof which cross-blocks the binding of an antibody of claim 11 to 13 to human TNF or is cross-blocked from binding human TNF by an antibody of claim 11 to 13.
22. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 21, which is humanized.
23. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 22, which has a binding affinity for human TNF of 150pM or higher affinity.
24. A multispecific antibody comprising an anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 15 or any one of claims 20 to 23.
25. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to 24.
26. A cloning or expression vector comprising one or more DNA sequences according to claim 25.
27. A vector according to claim 26, wherein the vector comprises (i) the sequence given in SEQ ID NO: 17, 18 and/or 22.
28. A host cell comprising one or more cloning or expression vectors according to claim 26 or claim 27.
29. A process for the production of an antibody having binding specificity for human TNF, comprising culturing the host cell of claim 28 and isolating the antibody.

30. A pharmaceutical composition comprising an anti-TNF antibody or binding fragment thereof as defined in any one of claims 1 to 24 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
31. A pharmaceutical composition according to claim 30 comprising other active ingredients.
32. An antibody or binding fragment thereof as defined in any one of claims 1 to 24 or a composition as defined in claim 30 or 31 for use in therapy.
33. An antibody or binding fragment thereof as defined in any one of claims 1 to 24 or a composition as defined in claim 30 or 31, for use in the treatment of one or more of autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; and cardiovascular disorders.
34. An antibody or binding fragment thereof as defined in any one of claims 1 to 24 or a composition as defined in claim 30 or 31 for use in the treatment of one or more of rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson’s disease and epilepsy.
35. Use of an antibody or binding fragment thereof as defined in any one of claims 1 to 24 or a composition as defined in claim 30 or claim 31 in the manufacture of a medicament for the treatment of one or more of autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; and cardiovascular disorders, wherein a patient is to be administered with a therapeutically effective amount of said antibody or binding fragment thereof or said composition.
36. Use of an antibody or binding fragment thereof as defined in any one of claims 1 to 24 or a composition as defined in claim 30 or claim 31 in the manufacture of a medicament for the treatment of one or more of rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson’s disease and epilepsy, wherein a patient is to be administered with a therapeutically effective amount of said antibody or binding fragment thereof or said composition.